Ovid Therapeutics Inc

+0.01 (+0.29%)

Ovid Therapeutics Announces Closing Of Agreement With Takeda For Global Development And Commercialization Of Soticlestat

Published: 03/30/2021 12:18 GMT
Ovid Therapeutics Inc (OVID) - Ovid Therapeutics Announces Closing of Agreement With Takeda for Global Development and Commercialization of Soticlestat.
Ovid Therapeutics Inc - at Closing, Ovid Received an Upfront Payment of $196 Million.
Ovid Therapeutics Inc - Ovid is Eligible to Receive Up to an Additional $660 Million Upon Achieving Development, Regulatory and Sales Milestones.
Ovid Therapeutics Inc - Will Receive Tiered Double-digit Royalties, Up to 20 Percent on Sales of Soticlestat, If Approved and Commercialized.